Literature DB >> 18559125

Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis.

C S Wang1, C J Yang, H C Chen, S H Chuang, I W Chong, J J Hwang, M S Huang.   

Abstract

Diabetes mellitus (DM) is a known risk factor for pulmonary tuberculosis (PTB). This study aimed to determine if type 2 DM alters manifestations and treatment outcome of PTB. Records of 217 consecutive culture-proven PTB patients were analysed retrospectively. The manifestations and treatment outcomes of 74 patients with type 2 DM (PTB-DM group) were compared to 143 patients without DM (PTB group). PTB-DM patients showed higher frequencies of fever, haemoptysis, positive acid-fast bacilli sputum smears, and consolidation, cavity, and lower lung field lesions on chest radiographs, and higher mortality rate. Furthermore, type 2 DM, age 65 years, and extensive radiographic disease were factors independently associated with an unfavorable outcome. This study confirmed that clinical manifestations and chest radiographs of PTB patients associated with type 2 DM significantly depart from the typical presentation. Type 2 DM seems to have a negative effect on treatment outcome of PTB.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559125     DOI: 10.1017/S0950268808000782

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  48 in total

Review 1.  Tuberculosis and diabetes mellitus: convergence of two epidemics.

Authors:  Kelly E Dooley; Richard E Chaisson
Journal:  Lancet Infect Dis       Date:  2009-12       Impact factor: 25.071

Review 2.  Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections.

Authors:  Kelly Hodgson; Jodie Morris; Tahnee Bridson; Brenda Govan; Catherine Rush; Natkunam Ketheesan
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

3.  Clinical characteristics, drug resistance, and treatment outcomes among tuberculosis patients with diabetes in Peru.

Authors:  M J Magee; E Bloss; S S Shin; C Contreras; H Arbanil Huaman; J Calderon Ticona; J Bayona; C Bonilla; M Yagui; O Jave; J P Cegielski
Journal:  Int J Infect Dis       Date:  2013-02-22       Impact factor: 3.623

4.  Degradation of myxovirus virion RNA by periodate.

Authors:  G A Tannock; I P Griffith
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

5.  Characteristics of patients with diabetes screened for tuberculosis in a tertiary care hospital in South India.

Authors:  S Kumpatla; A Sekar; S Achanta; B N Sharath; A M V Kumar; A D Harries; V Viswanathan
Journal:  Public Health Action       Date:  2013-11-04

6.  Diabetes mellitus is associated with cavities, smear grade, and multidrug-resistant tuberculosis in Georgia.

Authors:  M J Magee; R R Kempker; M Kipiani; N R Gandhi; L Darchia; N Tukvadze; P P Howards; K M V Narayan; H M Blumberg
Journal:  Int J Tuberc Lung Dis       Date:  2015-06       Impact factor: 2.373

7.  Convergence of tuberculosis and diabetes mellitus: time to individualise pharmaceutical care.

Authors:  Shubashini Gnanasan; Kang Nee Ting; Kok Thong Wong; Salmiah Mohd Ali; Abdul Razak Muttalif; Claire Anderson
Journal:  Int J Clin Pharm       Date:  2011-01-14

8.  The effect of diabetic control status on the clinical features of pulmonary tuberculosis.

Authors:  S W Park; J W Shin; J Y Kim; I W Park; B W Choi; J C Choi; Y S Kim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-25       Impact factor: 3.267

Review 9.  Is there an effect of glucose lowering treatment on incidence and prognosis of tuberculosis? A systematic review.

Authors:  Marit Eika Jørgensen; Daniel Faurholt-Jepsen
Journal:  Curr Diab Rep       Date:  2014-07       Impact factor: 4.810

10.  Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.

Authors:  A K Hemanth Kumar; V Chandrasekaran; T Kannan; A Lakshmi Murali; J Lavanya; V Sudha; Soumya Swaminathan; Geetha Ramachandran
Journal:  Eur J Clin Pharmacol       Date:  2016-09-20       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.